Added to YB: 2026-02-11
Pitch date: 2026-02-06
GSK [neutral]
GSK plc
+1.99%
current return
Author Info
No bio for this author
Company Info
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
Market Cap
GBP 86.9B
Pitch Price
GBP 21.83
Price Target
N/A
Dividend
3.33%
EV/EBITDA
7.63
P/E
15.60
EV/Sales
3.08
Sector
Pharmaceuticals
Category
value
Theodosian Capital | Stocks Update 6/2/2026 - GSK – Strong 2025, FX headwinds in 2026
GSK (update): Strong 2025 results with £32.7bn sales (+7% CER), specialty medicines +17%. Core EPS 172p (+12% YOY), FCF £4bn vs £2.9bn prior. 58 medicines/vaccines in pipeline, 5 FDA approvals. Guides 2026 3-5% revenue growth, 7-9% EPS growth despite FX headwinds. Trades 11.2x 2027 P/E, 3.4% yield.
Read full article (2 min)